Dihydroergotamine (DHE) is commonly used for status migrainosus via which routes?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

For status migrainosus, delivering the drug quickly and reliably is essential, and that means choosing routes that bypass the gastrointestinal tract and first-pass metabolism. Dihydroergotamine has very poor oral bioavailability, with absorption that is both limited and unreliable—especially during a prolonged or vomiting-prone migraine attack—so oral administration is not dependable. The intravenous route provides immediate, controllable plasma levels, making it a go-to option in hospital settings for rapidly stopping a severe, ongoing attack. The intranasal form also offers rapid absorption through the nasal mucosa, bypassing the liver and allowing fast onset without an IV line, which is particularly useful for quicker, outpatient management. In contrast, intramuscular dosing is slower and less predictable, and inhaled administration is not the standard approach for this indication, so IV or nasal routes are the preferred options.